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Spontaneous Splenic Rupture as Manifestation
of the Immune Reconstitution Inflammatory
Syndrome in an HIV Type 1 Infected
Patient with Tuberculosis
The immune reconstitution inflammatory syndrome
(IRIS) is associated with the initiation of highly active
antiretroviral therapy (HAART) in HIV-infected patients
[1, 2]. The spectrum of clinical presentations ranges from
a worsening of opportunistic infection under treatment to
the atypical appearance of an unrecognized opportunistic
infection to autoimmune disorders, such as Graves’ dis-
ease [3]. Paradoxical responses during treatment for
Mycobacterium tuberculosis (MTB) infection in non-HIV-
infected patients had been recognized even prior to the
advent of HAART [4, 5]. Clinical worsening in these
patients was attributed to the reversal of MTB infection-
induced immunosuppression and associated with the
conversion of MTB skin tests from negative to positive
[6]. In accordance with these assumptions, such patients
were found to show improved pathogen-specific immune
responses, based on delayed hypersensitivity testing or
more advanced T cell techniques [4, 7]. However, dereg-
ulation of specific T cell responses has also been reported
[8]. A rapid improvement of cellular immunity against
specific antigens due to HAART may lead to symptom-
atic systemic inflammation. Consequently, anti-inflam-
matory treatment is required in severe cases of IRIS,
which are potentially fatal, especially when the nervous
system is involved [9, 10].
A 36-year-old native of Thailand presented to the
emergency room with shortness of breath and fever
lasting for 14 days. HIV infection with a CD4 count of
102 cells/ll had been diagnosed 3 years earlier. Antiret-
roviral treatment consisting of lopinavir/ritonavir, zido-
vudine and lamivudine was initiated at that time, and
within 6 months the viremia was suppressed and the CD4
count increased to 300 cells/ll. One year later, he inter-
rupted antiretroviral treatment and was lost to follow up.
On admission, his temperature was 39 C, blood pressure,
102/73 mmHg, pulse, 120/min, and frequency of respira-
tion, 24 breaths/min. Physical examination of the trans-
sexual man with silicon-breast implants showed normal
clinical findings. Laboratory tests revealed an elevated
level of C-reactive protein (CRP) of 167 mg/l, and normo-
cytic anemia with a hemoglobin count of 5.4 g/dl; the
plasma HIV RNA level was 469,000 copies/ml and the
CD4 count 9 cells/ll. A chest CT scan showed diffuse
bilateral infiltrates, and a bronchoalveolar lavage (BAL)
specimen revealed Pneumocystis jirovecii infection.
Treatment with trimethoprim–sulfamethoxazole was
started without steroids because of a pO2 of 11 kPa.
One week later, cultures for MTB from sputum and
BAL samples were reported to be positive. Histological
examination of a fine needle aspirate obtained from a
mediastinal lymph node showed necrotizing, caseating
granuloma with a high load of Ziehl–Neelsen-stained
acid-fast bacilli. Antituberculous treatment with isoniazid,
rifampicin, ethambutol, and pyrazinamid was started (day
7 after admission). The patient recovered rapidly and
became afebrile; pulmonary oxygenation normalized,
CRP normalized to 5 mg/l, and the hemoglobin level rose
to 8.9 g/dl 2 weeks after starting antituberculous therapy
(day 21). At this time it was decided to initiate HAART
with lamivudine, zidovudine, and nevirapine. This early
time point to start HAART was chosen in order (1) to
optimize the complex antimicrobial therapies during the
hospital stay, (2) to control for drug interactions, and (3)
to guarantee treatment adherence of the homeless patient.
Ten days after initiating HAART (day 31) relapsing
fevers recurred twice daily with temperatures of up to
40 C, cutaneous lesions were noticed (tuberculide),
and the patient fell short of breath again. Repeated
blood, urine, and stool cultures remained negative for
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additional microorganisms, and chest X-ray revealed no
new infiltrates; the CRP was 335 mg/l. A diagnosis of
IRIS was postulated and, subsequently, a therapy with
prednisone 50 mg per day was started. The rise of the
initial CD4 count of 9 (6%) to 45 (29%) cells/ll on day 31
within only 10 days of HAART was accompanied by a
drop in the viral load from 469,000 to 894 copies/ll and
strongly supported the diagnosis IRIS. Three days after
starting prednisone (day 34) and without any trauma in
the meantime, the patient complained of strong abdomi-
nal pain localizing in the left upper quadrant and of
modest diarrhea. A contrast-enhanced abdominal CT scan
demonstrated an increase of splenomegaly to 15.80 cm,
which had been already present in the CT scan on
admission (13.56 cm), and further enlargement of the
mediastinal and abdominal lymph nodes, whereas the size
of the liver did not change. Importantly, splenic rupture
without active bleeding and without splenic abscess was
diagnosed (Figure 1). Due to this potentially life-threat-
ening condition, the patient was monitored for 24 h in the
intensive care unit under strict bed rest: blood pressure
remained stable around 100/70 mmHg, and hemoglobin
was regularly measured at a level of 9 g/dl. The platelet
count was 298 · 103/ll and the international normalized
ratio (INR) was 0.9, excluding a coagulopathy or bleeding
tendency. Splenectomy was considered together with vis-
ceral surgery consultants, but it was deferred due to the
stable clinical evolution and the substantial risks of the
low immune status of the patient. Treatment with pred-
nisone, HAART, and antituberculous drugs for presum-
able disseminated tuberculosis was continued. After
3 days, the patient was painless, but continued to be feb-
rile, and a follow up CT scan showed no changes in the
size of the spleen (15 cm, day 37) or the splenic rupture.
One month after the diagnosis of splenic rupture (day 67),
the patient was afebrile, doing well, and was discharged on
15 mg prednisone, HAART (zidovudine, lamivudine,
nevirapine), and antituberculous treatment with rifampi-
cin and isoniazid. Another CT scan 8 weeks later (day
123) showed reversion of splenomegaly back to a base-
line of 12 cm and disappearance of the signs of splenic
rupture.
IRIS in HIV-infected patients treated for MTB
infection was first described in the mid-1990s, when HA-
ART became widely available. IRIS usually occurs within
the first 2–3 months after initiation of HAART, with a
median interval to the onset of symptoms due to MTB
infections or cryptococcosis of 11 days [11]. However,
rarely it can be diagnosed after 1 or 2 years of therapy.
The questions of whether the occurrence of IRIS is
related to the time between initiating treatment for an
underlying opportunistic infection and starting HAART
and when to start HAART optimally are still a matter of
debate [2, 12]. However, it has been shown that the vast
majority of MTB-related IRIS occurs within the first
4 weeks of the initiation of HAART [13, 14]. An increase
of respiratory symptoms has been reported in patients
with IRIS under treatment for HIV and MTB [15, 16], and
paradoxical clinical worsening has been reported to have
occurred in about 35% of patients [7, 17]. The presenta-
tions include prolonged fever, augmented cough or
shortness of breath, hepatosplenomegaly, lymphadenop-
athy, and the development of cutaneous lesions and
ascites. Most of these clinical findings are common and
were also present in the case under discussion here.
However only two cases of splenic abscess and rupture as
Figure 1. (a) Contrast-enhanced
transverse CT of the abdomen
showing the size of the spleen
(13.6 cm) on admission.
(b) Contrast-enhanced
transverse CT of the abdomen
on day 34 showing
splenomegaly (15.8 cm), with a
low-density linear area
stretching centripetally from
the capsule typical for splenic
rupture (arrow) as well as
necrotizing retroperitoneal
lymphadenopathy
(arrowheads). No evidence of
bleeding or free fluid in the
abdomen was present.
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a consequence of IRIS and MTB infection have been
described in the literature to date [18, 19]. In both cases,
the spleen was removed and MTB infection was discov-
ered in the specimen. In one case, splenectomy was per-
formed upon demonstration of intraperitoneal blood by
paracentesis; in the other case, the removal of the spleen
was a preventive procedure. Following multidisciplinary
evaluations, we decided to follow a conservative proce-
dure in our case because of the absence of acute bleeding
and/or sepsis, the relatively small size of the rupture, the
surgical risk of this immunocompromised patient, and the
patient’s stable hemoglobin, blood pressure, and clinical
presentation. The spleen was most likely infected by MTB
in the context of disseminated tuberculosis, although
infection was only formally demonstrated in the lymph
node and the lung; nevertheless, we strongly believe that
the reason for the observed spontaneous splenic rupture
was the rapid increase in size of the spleen following
the initiation of HAART. Interruption of HAART was
taken into consideration but finally rejected because of
the stable clinical situation.
In summary, splenic rupture represents a rare com-
plication of a MTB infection related to IRIS in HIV-in-
fected patients [20]. Whereas splenectomy was performed
in two previously published cases of splenic rupture, our
patient represents the first case successfully managed
without splenectomy. In conclusion, the occurrence of
abdominal pain in an HIV-infected patient with IRIS
should provoke imaging to exclude splenic rupture that is
potentially rapidly fatal.
E. Weber, H.F. Gu¨nthard, T. Schertler, J.D. Seebach
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